PRQR — ProQR Therapeutics NV Share Price
0.000.00%
Last trade - 00:00- $150.38m
- $59.57m
- €9.53m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.87 | ||
| Price to Tang. Book | 3.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.99 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -32.52% | ||
| Return on Equity | -57.22% | ||
| Operating Margin | -215.65% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 1.93 | 9.45 | 2.38 | 4.36 | 9.53 | 22.08 | 21.36 | 10.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Directors
- Dinko Valerio CSU (64)
- Daniel De Boer CMG (38)
- Theresa Heggie OTH (60)
- Bart Filius IND (50)
- Alison Lawton IND (59)
- Antoine Papiernik IND (55)
- James Shannon IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 21st, 2012
- Public Since
- September 18th, 2014
- No. of Employees
- 157
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 84,248,384
- Address
- Zernikedreef 9, LEIDEN, 2333 CK
- Web
- https://www.proqr.com/
- Phone
- +31 854894932
- Contact
- Sarah Kiely
- Auditors
- Deloitte Accountants B.V.
Upcoming Events for PRQR
Similar to PRQR
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the ProQR Therapeutics NV share price?
As of Today at 22:46 UTC, shares in ProQR Therapeutics NV are trading at $1.71. This share price information is delayed by 15 minutes.
How has the ProQR Therapeutics NV share price performed this year?
Shares in ProQR Therapeutics NV last closed at $1.71 and the price had moved by over the past 365 days. In terms of relative price strength the ProQR Therapeutics NV share price has underperformed the S&P500 Index by -20.43% over the past year.
What are the analyst and broker recommendations for ProQR Therapeutics NV?
The overall consensus recommendation for ProQR Therapeutics NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the ProQR Therapeutics NV dividend yield?
ProQR Therapeutics NV does not currently pay a dividend.
Does ProQR Therapeutics NV pay a dividend?
ProQR Therapeutics NV does not currently pay a dividend.
When does ProQR Therapeutics NV next pay dividends?
ProQR Therapeutics NV does not currently pay a dividend.
How do I buy ProQR Therapeutics NV shares?
To buy shares in ProQR Therapeutics NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ProQR Therapeutics NV?
As of the previous close price of $1.71, shares in ProQR Therapeutics NV had a market capitalisation of $144.06m.
Where are ProQR Therapeutics NV shares listed?
Here are the trading details for ProQR Therapeutics NV:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PRQR
What kind of share is ProQR Therapeutics NV?
Based on an overall assessment of its quality, value and momentum ProQR Therapeutics NV is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ProQR Therapeutics NV share price forecast for 2024?
The analyst consensus target price for shares in ProQR Therapeutics NV is $4.24. That is 147.79% above the last closing price of $1.71.
Analysts covering ProQR Therapeutics NV currently have a consensus Earnings Per Share (EPS) forecast of -€0.47 for the next financial year.
What is the trend in the ProQR Therapeutics NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ProQR Therapeutics NV. Over the past six months, its share price has underperformed the S&P500 Index by -21.36%.
As of the last closing price of $1.71, shares in ProQR Therapeutics NV were trading -7.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ProQR Therapeutics NV PE Ratio?
The ProQR Therapeutics NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.71.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ProQR Therapeutics NV?
ProQR Therapeutics NV's management team is headed by:
- Dinko Valerio - CSU
- Daniel De Boer - CMG
- Theresa Heggie - OTH
- Bart Filius - IND
- Alison Lawton - IND
- Antoine Papiernik - IND
- James Shannon - IND